AlzeCure Announces Positive Data From Its First Clinical Study of ACD856

AlzeCure Announces Positive Data From Its First Clinical Study of ACD856
AlzeCure Pharma announced positive results from its first clinical study of ACD856 for the potential treatment of Alzheimer's disease. According to the company, ACD856 showed a good pharmacokinetic profile — namely a significantly shorter human half-life than its predecessor, ACD855 — and suitability for further clinical development as an oral medication for Alzheimer's. Pharmacokinetics refers, essentially, to how the body affects a medicine. The half-life of a compound refers to how long it takes for half of the initial dose that entered the body to be processed and eliminated from the bloodstream. “We are very pleased that ACD856 has a suitable profile for further clinical development,” said Johan Sandin, PhD, chief scientific officer of AlzeCure, in a company press release. “The compound has previously shown potent cognitive and memory enhancing properties in our preclinical studies.” “With its potential to improve memory functions in a variety of disorders, ACD856 can play a significant role in treating indications where these key functions are impaired, such as Alzheimer’s disease, sleep apnea, traumatic brain injury and Parkinson’s disease,” he added. AlzeCure plans to begin Phase 1 clinical trials by the end of 2020 to evaluate ACD856's tolerability and early efficacy in humans. ACD856 is currently the company
Subscribe or to access all post and page content.